LATAMBif Registry: January 2021 Report

The Latin American Registry of Percutaneous Coronary Bifurcations continues to develop at a steady pace. The aim of this prospective multicenter registry is to assess the reality of percutaneous coronary bifurcation to define its needs and establish effective strategies to perfect the daily clinical practice. 

Bellow you will find data from January 2021, which includes all patients enrolled by the different Latin American centers taking part in the register. 

January data

So far, the registry has included 157 patients of mean age 65 (+- 10.86): 85% men, and 15% women.

Among the risk factors, we have found 84,6% had a history of hypertension, 78,2% dyslipidemia, 12,2% were smokers, 17,9% had type 2 diabetes and 2,6% had type 1 diabetes. In addition, 42,9% had prior PCI, 7,1% prior CABG and 26,9% prior MI.

Registro LATAM BIF - Reporte Mensual Enero 2021

Of all included patients, 37,2% presented chromic coronary syndrome, 26,9% unstable angina, 16,7% Non-ST acute myocardial infarction (NSTEMI), 12,2% were asymptomatic (silent ischemia) 7,1 ST elevation MI (STEMI).

As regards clinical indications, 55,1% received elective indication, 35,3% urgent indication and 9,6 emergency indication.

83,2% of vascular access was transradial (proximal), 3,9% transradial (distal) and12,9% femoral.

Registro Latam Bif - Reporte Mensual Enero 2021 - 2

As to the initial strategy, 71% was the provisional stent technique and 29% the two stent technique.

Registro Latam Bif - Reporte Mensual Enero 2021 - 3
monthly-report-january-2021

How to make part of the LATAM Bif Registry?

Write to latambif@gmail.com. You will receive all the information and documentation required for LATAMBif, coordinated by SOLACI Research.

Why take part in LATAM Bif?

  1. The chance to access your own database dedicated to coronary bifurcations, with unified variables for all centers across Latin America. 
  2. Each center will own their data and will be able to analyze outcomes in real time. 
  3. The chance to interact with centers interested in research and publication throughout the region. 
  4. The chance to present at local and international events the outcomes of LATAM Bif Registry.
  5. In case you might need help to develop research projects and/or carry out statistical analysis, you will have the support of SOLACI Research.
  6. SOLACI Research will provide weekly auditing for all data, initial and annual (mandatory followup), for it to be charged correctly. 

Write now to latambif@gmail.com and start participating of LATAM Bif.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

The El Salvador 2024 Sessions are coming soon

The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Check out the best images of the Arequipa 2024 Sessions

Review the highlights of the XVIII SOLACI Regional Sessions held at the Hanan Hotel in Arequipa, Peru between October 3 and 4, 2024. <!-- wp:tw/bwg...

Virtual Event SOLACI-Medtronic | The Visible Heart Lab

We invite you to participate in a new virtual activity organized in collaboration with Medtronic, focused on "The Visible Heart Lab" and dedicated to...

SOLACI-CACI 2024 – Presentations day 3

Discover the highlights of the third day of activities of  SOLACI-CACI 2024 Congress, held from August 7 to 9 at the Hilton Hotel in Buenos Aires, Argentina. Dr....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | Asymptomatic Severe Aortic Stenosis: What Should Be our Approach?

Approximately 3% of the population over 65 years old has aortic stenosis. Current guidelines recommend valve replacement for patients with symptoms or an ejection...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...